Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 3Phase 3 2Phase 1 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1

Conditions

Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × futuximab × Clear all
NCT02568046 2019-03-26

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

Symphogen A/S

Phase 1/2 Terminated
10 enrolled 14 charts
Gastrointestinal

Colorectal Neoplasms

NCT01117428 2018-10-15

Sym004 in Patients With Advanced Solid Tumors

Symphogen A/S

Phase 1/2 Completed
111 enrolled 18 charts
Gastrointestinal

Colorectal Neoplasms

NCT02924233 2017-08-28

Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer

Symphogen A/S

Phase 1/2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡